Organic compounds -- part of the class 532-570 series – Organic compounds – Carbohydrates or derivatives
Reexamination Certificate
2007-11-27
2007-11-27
Whiteman, Brian (Department: 1635)
Organic compounds -- part of the class 532-570 series
Organic compounds
Carbohydrates or derivatives
Reexamination Certificate
active
10727358
ABSTRACT:
The present invention relates to methods and compositions for the specific inhibition of kinase suppressor of Ras (KSR). In particular, the invention provides genetic approaches and nucleic acids for the specific inhibition of KSR, particularly of KSR expression. The invention relates to antisense oligonucleotides and the expression of nucleic acid which is substantially complementary to KSR RNA. Oligonucleotide and nucleic acid compositions are provided. The invention provides methods to inhibit KSR, including inhibition of KSR expression. Methods for blocking gƒ Ras mediated tumorigenesis, metastasis, and for cancer therapy are provided. Methods for conferring radiosensitivity to cells are also provided.
REFERENCES:
patent: 4016043 (1977-04-01), Schuurs et al.
patent: 5591721 (1997-01-01), Agrawal et al.
patent: 5700675 (1997-12-01), Rubin et al.
patent: 5747275 (1998-05-01), Rubin et al.
patent: 5747288 (1998-05-01), Rubin et al.
patent: 6261834 (2001-07-01), Srivastava
patent: 6277981 (2001-08-01), Tu et al.
patent: 6329203 (2001-12-01), Bennett et al.
patent: 6416951 (2002-07-01), Schmidt et al.
patent: 6500615 (2002-12-01), Schmidt et al.
patent: 2003/0051267 (2003-03-01), McNeish et al.
patent: 2003/0109466 (2003-06-01), Monia et al.
patent: WO97/21820 (1997-06-01), None
patent: WO03025144 (2003-03-01), None
patent: 03/016961 (2003-05-01), None
WO 99/27105 (abstract only) attached is the result #9 of sequence search result against SEQ ID No.: 5 performed on Oct. 30, 2006.
Agrawal, S., Temsamani, J. & Tang, Y.Y. (1991) Proc. Natl. Acad Sci U.S.A. 88:7595-7599.
Bernhard, E.J. et al. (2000) Cancer Res. 60:6597-6600.
Dean et al. (1994) J. Biol. Chem. 269:16446-16424.
Duff et al. (1995) J. Biol. Chem. 270:7161-7166.
Genbank Accession No. U43585; ROD Jan. 30, 1996.
Genbank Accession NM—013571; ROD Jan. 7, 2002.
Gupta, A.K. et al. (2001) Cancer Ras 61:4278-4282.
Ho et al. (1996) Nucl Acids Res 24:1901-1907.
Ho et al. (1998) Nature Biotechnology 16:59-630.
Kabanov, et al. (1990) FEBS Lett. 259:327.
Lozano, J. et al (2003) Cancer Research 63:4232-4238.
Monia et al. (1992) J. Biol. Chem. 267:19954-19962.
Nguyen, A. et al. (2002) Mol. Cell Biol. 22:3035-3045.
Therrien, M. et al. (1995) Cell 83:879-888.
Wang et al. (1995) Proc. Natl. Acad. Sci. USA 92:3318-3322.
Xing, H.R., Lozano, J. and Kolesnick, R. (2000) J. Biol. Chem. 275:17267-17280.
Xing, H.R. and Kolesnick, R. (2001) J. Biol. Chem. 276: 9733-9741.
Xing, H.R. and Kolesnick, R. (2002) Proc. Amer. Assoc. Cancer Res. 43:720 (Abstract #3571).
Xing, H.R. et al. (2003) Nature Med. 9:1266-1268 (Epub Sep. 7, 2003).
Xing, H.R. et al. (2003) Proc. Amer. Assoc. Cancer Res. 44(2):192 (Abstract #960).
Yamagami et al. (1996) Blood 87:2878-2884.
Almoguera, C. et al (1988) Cell. 53:549-554.
Balaban, N. et al. (1996) Biochim Biophys Acta. 1314:147-156.
Banerjee, D. (2001) Curr Opin Investig Drugs 2:574-580.
Bennett et al. (1994) J. Immunol. 152:3530-3540.
Bernhard, E.J. et al. (1998) Cancer Res. 58:1754-1761.
Bos, J. (1989) Cancer Res. 49: 4683-4689.
Brummelkamp, T.R. et al. (2002) Cancer Cell 2:243-247.
Denouel-Galy, A. et al. (1998) Curr. Biol. 8:46-55.
Geary, R.S. et al. (1997) Anticancer Drug Des 12:383-393.
Gokhale, P.C. et al. (1999) Antisense Nucleic Acid Dru Dev. 9:191-201.
Grant, M.L. et al. (1990) Oncogene 5:1159-1164.
Gupta, A.K. et al. (2000) Radiat Res. 154:64-72.
Henry, S.P. et al. (1997) Anticancer Drug Des 12:395-408.
Jones, H. et al. (2001) Semin Radiat Oncol. 11:328-337.
Kornfeld, K., Hom, D.B. & Horvitz, H.R. (1995) Cell 83:903-913.
Kushner, D.M. and Silverman, R.H. (2000) Curr Oncol Rep 2:23-30.
Laptev et al. (1994) Biochem. 33:11033-11039.
Migley, R.S. and Kerr, D.J. (2002) Crit Rev Oncol Hematol. 44:109-120.
Mishra et al. (1994) Life Sciences 317:977-982.
McKenna, W.G. et al. (1990) Cancer Res 50:97-102.
Ogiso, Y. et al. (1994) Gene Ther 1:403-407.
Ohmachi, M. et al. (2002) Curr Biol 12:427-433.
Ojala et al (1997) Antisense Nucl Drug Dev. 7:31-38.
Sundaram, M. & Han, M. (1995) Cell 83:889-901.
Xing, H., Kornfeld, K. & Muslin, A.J. (1997) Curr. Biol. 7:294-300.
Yao, B. et al. (1995) Nature 378:307-310.
Zhang, Y. et al. (1997) Cell 89:63-72.
Roy, Francis et al, 2002, KSR is a scaffold required for activation of the ERK/MARK module, Genes & Development vol. 16, No. 4, pp. 427-438.
Yan, F, et al, 2001, Cancer Research, Kinase Suppressor of Ras Determines Survival of Intestinal Epithelial Cells Exposed in tumor Necrosis Factor, vol. 16, pp. 8668-8675.
Kolesnick Richard N.
Xing Hongmei R.
Klauber & Jackson LLC
Whiteman Brian
LandOfFree
Kinase suppressor of Ras inactivation for therapy of Ras... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Kinase suppressor of Ras inactivation for therapy of Ras..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Kinase suppressor of Ras inactivation for therapy of Ras... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3812873